NASDAQ:CDXS - Nasdaq - US1920051067 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to CDXS. CDXS was compared to 55 industry peers in the Life Sciences Tools & Services industry. CDXS may be in some trouble as it scores bad on both profitability and health. CDXS is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -57.77% | ||
ROE | -150.03% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 71.56% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.59 | ||
Debt/FCF | N/A | ||
Altman-Z | -5.66 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.72 | ||
Quick Ratio | 3.64 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.35
+0.02 (+0.86%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.91 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 3.92 | ||
P/tB | 4.13 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -57.77% | ||
ROE | -150.03% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 71.56% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.59 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 90.63% | ||
Cap/Sales | 8.89% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.72 | ||
Quick Ratio | 3.64 | ||
Altman-Z | -5.66 |